Replies to post #246859 on Biotech Values

[iwfal]

RETA - credit where credit is due.

RETA -22% of discontinuation of Bardoxolone program

PGS was first in this community to notice that RETA was (very effectively) gaming the trial results by using creatinine to estimate GFR (among other things).

[DewDiligence]

BIIB acquires RETA for $172.50 cash—a 59% premium to yesterday’s close:

https://finance.yahoo.com/news/biogen-acquire-reata-pharmaceuticals-110500753.html

The nominal deal value is $7.3B.